Inolimomab

Inolimomab
Monoclonal antibody
TypeWhole antibody
SourceMouse
TargetCD25
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
 ☒NcheckY (what is this?)  (verify)

Inolimomab is a mouse monoclonal antibody developed as an immunosuppressive drug against graft-versus-host disease. Its target is the alpha chain of the interleukin-2 receptor.[1][2]

References

  1. ^ Piñana JL, Valcárcel D, Martino R, Moreno ME, Sureda A, Briones J, et al. (November 2006). "Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease". Biology of Blood and Marrow Transplantation. 12 (11): 1135–1141. doi:10.1016/j.bbmt.2006.06.010. PMID 17085306.
  2. ^ Dartois C, Freyer G, Michallet M, Hénin E, You B, Darlavoix I, et al. (2007). "Exposure-effect population model of inolimomab, a monoclonal antibody administered in first-line treatment for acute graft-versus-host disease". Clinical Pharmacokinetics. 46 (5): 417–432. doi:10.2165/00003088-200746050-00004. PMC 2760126. PMID 17465640.
Stub icon

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.